Saladax Biomedical, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York City

BETHLEHEM, Pa., Sept.12, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a commercial-stage, companion diagnostic company with an existing pipeline that enables personalized medicine, announced today that Kevin M. Harter, president and CEO of Saladax, will be presenting at the UBS Global Life Sciences Conference at 11 a.m. ET on September 19, 2012 at the Grand Hyatt in New York City. 

Mr. Harter will provide an overview of the company's business, strategic partnerships and its products, which consist of 19 assays designed to improve the effectiveness and safety of pharmaceutical drugs; 15 of which are proprietary diagnostic assays that improve the dosing of oncology and central nervous system (CNS) drugs.  By measuring and providing information on drug exposure, Saladax provides physicians a tool to manage their patients' care and generate optimal outcomes by minimizing side effects, improving quality of life and reducing overall costs of care.

About Saladax Biomedical, Inc.

Saladax Biomedical develops novel diagnostic assays for the practical delivery of personalized medicine.  Our proprietary line of MyCare™ assays improves the efficacy of existing drugs by optimizing the dose administered for each individual patient.  Saladax's initial focus is oncology, with a portfolio of 13 chemotherapy drug assays in various stages of development.  Three MyCare assays, My5- FU™, MyPaclitaxel™ and MyDocetaxel™, are currently offered to the oncology community in markets around the world.

The company's MyCare technology platform is broad and flexible, enabling wide application in many therapeutic categories.  This technology capability also enables Saladax to serve as a valuable partner to pharmaceutical and biotechnology companies in the development of companion diagnostics (CDx), addressing multiple risks and challenges encountered in drug development.

The company was founded in 2004 and is headquartered in Bethlehem, Pennsylvania.  Saladax is ISO 13485:2003 certified.

Saladax Biomedical, Inc.
Kevin M. Harter
President and Chief Executive Officer
[email protected]

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
[email protected]
or
Claire Sojda
[email protected]

SOURCE Saladax Biomedical, Inc.